Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy

Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy

Abstract This report describes the case of a 70-year-old man with metastatic squamous cell carcinoma (SCC) of the right lower leg. Soon after definitive surgical management of the primary and nodal metastases with curative intent, he relapsed, developing aggressive in-transit metastatic disease and...

Full description

Bibliographic Details
Main Authors:	Chris Furkert, Richard Martin, Avinash Sharma, Gareth Rivalland
Format:	Article
Language:	English
Published:	BMC 2023-09-01
Series:	World Journal of Surgical Oncology
Subjects:	Squamous cell carcinoma In-transit In-transit metastases Immunotherapy Anti-PD-1
Online Access:	https://doi.org/10.1186/s12957-023-03179-3

Similar Items

Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma
by: Jennifer E. Yeh, MD, PhD, et al.
Published: (2022-09-01)

Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma
by: Luke S. McLean, et al.
Published: (2022-01-01)

Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
by: Natalia García-Sancha, et al.
Published: (2021-10-01)

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
by: Zhenlin Yang, et al.
Published: (2022-10-01)

Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma
by: Adam Khorasanchi, et al.
Published: (2022-10-01)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
by: Marcos Oro-Ayude, et al.
Published: (2020-02-01)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
by: Yaxiong Zhang, et al.
Published: (2018-12-01)

Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma
by: Cui P, et al.
Published: (2020-07-01)

Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
by: Hanieh Zargham, MD, et al.
Published: (2022-08-01)

Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
by: Piero Giuseppe Meliante, et al.
Published: (2023-02-01)

Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01)

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review
by: Xiangrong Zhao, et al.
Published: (2020-09-01)

Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma
by: Annette M. Lim, et al.
Published: (2021-04-01)

Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
by: Michael Lattanzi, et al.
Published: (2018-10-01)

Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
by: Kate Clancy, et al.
Published: (2021-09-01)

Squamous papillary carcinoma with transitional differenciation of the endometrium: an uncommon condition
by: Mustapha Azzakhmam, et al.
Published: (2020-02-01)

CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways
by: Xiyang Tang, et al.
Published: (2022-11-01)

Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy
by: Karda Cavanagh, et al.
Published: (2024-03-01)

Anti‐PD‐1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report
by: Abdurahman Alloghbi, et al.
Published: (2021-12-01)

Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
by: Maite Alvarez, et al.
Published: (2023-12-01)

Sex as a Predictor of Response to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
by: Nicholas Yeo, et al.
Published: (2023-10-01)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
by: Liping Pei, et al.
Published: (2023-02-01)

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma
by: Andrea Boutros, et al.
Published: (2021-08-01)

Case Report: Squamous Cell Carcinoma of Pancreas With High PD-L1 Expression: A Rare Presentation
by: Baohong Yang, et al.
Published: (2021-07-01)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
by: Kim A. Brogden, et al.
Published: (2018-02-01)

PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
by: Alexander Yakobson, et al.
Published: (2023-08-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
by: Julian A. Marin-Acevedo, et al.
Published: (2023-06-01)

Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab – a case report
by: Simon Fietz, et al.
Published: (2023-12-01)

Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy
by: Xiaolu Ma, et al.
Published: (2022-11-01)

Editorial: Natural products modulate the sensitivity of cancer to anti-PD-1 based immunotherapy
by: Jean Christopher Chamcheu, et al.
Published: (2023-06-01)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
by: Sarah C. Cowles, et al.
Published: (2022-12-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
by: Yui Hirata-Nozaki, et al.
Published: (2019-06-01)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)

Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma
by: Feng L, et al.
Published: (2022-09-01)

Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
by: Sadique A. Javed, et al.
Published: (2024-04-01)